Clarity Pharmaceuticals Ltd (CU6.AX)
| Previous close | 3.0100 |
| Open | 3.0700 |
| Bid | 3.2600 x N/A |
| Ask | 3.2900 x N/A |
| Day's range | 3.0300 - 3.3100 |
| 52-week range | 0.6750 - 3.3100 |
| Volume | |
| Avg. volume | 586,403 |
| Market cap | 1.016B |
| Beta (5Y monthly) | 1.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.37 |
PR NewswireClarity's theranostic prostate cancer trial advances to multi-dose phase
Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the successful completion of cohort 3 and advancement to cohort 4, the first multi-dose cohort in the SECuRE trial.
PR NewswireAdditional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range
Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to share additional data from its diagnostic 64Cu-SAR-bisPSMA trial, COBRA (NCT05249127)[1].
PR NewswireFirst patient dosed in Clarity's registrational Phase III prostate cancer trial with Cu-64 SAR-bisPSMA
Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the first patient has been dosed in its pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY (NCT06056830)1, at the Urology Cancer Center / XCancer Omaha, NE.
